1. Home
  2. ONCO vs ENSC Comparison

ONCO vs ENSC Comparison

Compare ONCO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONCO
  • ENSC
  • Stock Information
  • Founded
  • ONCO 2018
  • ENSC 2003
  • Country
  • ONCO United States
  • ENSC United States
  • Employees
  • ONCO N/A
  • ENSC N/A
  • Industry
  • ONCO Biotechnology: Pharmaceutical Preparations
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • ONCO Health Care
  • ENSC Health Care
  • Exchange
  • ONCO Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • ONCO 9.4M
  • ENSC 7.9M
  • IPO Year
  • ONCO 2022
  • ENSC N/A
  • Fundamental
  • Price
  • ONCO $0.60
  • ENSC $6.22
  • Analyst Decision
  • ONCO
  • ENSC
  • Analyst Count
  • ONCO 0
  • ENSC 0
  • Target Price
  • ONCO N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • ONCO 10.4M
  • ENSC 58.7K
  • Earning Date
  • ONCO 12-10-2024
  • ENSC 03-14-2025
  • Dividend Yield
  • ONCO N/A
  • ENSC N/A
  • EPS Growth
  • ONCO N/A
  • ENSC N/A
  • EPS
  • ONCO N/A
  • ENSC N/A
  • Revenue
  • ONCO $1,870,605.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • ONCO N/A
  • ENSC $89.78
  • Revenue Next Year
  • ONCO N/A
  • ENSC N/A
  • P/E Ratio
  • ONCO N/A
  • ENSC N/A
  • Revenue Growth
  • ONCO N/A
  • ENSC 40.41
  • 52 Week Low
  • ONCO $0.32
  • ENSC $2.12
  • 52 Week High
  • ONCO $21.40
  • ENSC $21.00
  • Technical
  • Relative Strength Index (RSI)
  • ONCO 51.04
  • ENSC 40.62
  • Support Level
  • ONCO $0.51
  • ENSC $5.55
  • Resistance Level
  • ONCO $0.70
  • ENSC $7.36
  • Average True Range (ATR)
  • ONCO 0.09
  • ENSC 0.67
  • MACD
  • ONCO 0.03
  • ENSC -0.13
  • Stochastic Oscillator
  • ONCO 34.45
  • ENSC 24.86

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: